National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings, 3799-3800 [2017-00477]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 8 / Thursday, January 12, 2017 / Notices
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: January 6, 2017.
Janice M. Soreth,
Associate Commissioner, Special Medical
Programs.
[FR Doc. 2017–00496 Filed 1–11–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0001]
Vaccines and Related Biological
Products Advisory Committee; Notice
of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Vaccines and Related
Biological Products Advisory
Committee. The general function of the
committee is to provide advice and
recommendations to the Agency on
FDA’s regulatory issues. The meeting
will be open to the public.
DATES: The meeting will be held on
March 9, 2017, from 8:30 a.m. to 3 p.m.
ADDRESSES: National Institutes of Health
(NIH), Fishers Lane Conference Center,
5635 Fishers Lane, Rockville, MD
20852. Enter through the main front
entrance on Fishers Lane. Take the
elevators down to the T-Terrace Level.
Follow the short hallway towards the
elevators and the Conference Center
glass doors are straight ahead near the
elevators.
For those unable to attend in person,
the meeting will also be Web cast and
will be available at the following link:
https://videocast.nih.gov/. Answers to
commonly asked questions including
information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
FOR FURTHER INFORMATION CONTACT:
Prabhakara Atreya or Rosanna Harvey,
Center for Biologics Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 71, Rm. 6306, Silver Spring,
mstockstill on DSK3G9T082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:28 Jan 11, 2017
Jkt 241001
MD 20993–0002, at 240–402–8006,
prabhakara.atreya@fda.hhs.gov and
240–402–8072, rosanna.harvey@
fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
SUPPLEMENTARY INFORMATION:
Agenda: On March 9, 2017, the
committee will meet in open session to
discuss and make recommendations on
the selection of strains to be included in
the influenza virus vaccines for the
2017–2018 influenza season.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before February 23, 2017.
Oral presentations from the public will
be scheduled between approximately
12:50 p.m. and 1:50 p.m. Those
individuals interested in making formal
oral presentations should notify the
contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before February 14, 2017. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
PO 00000
Frm 00084
Fmt 4703
Sfmt 4703
3799
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
February 15, 2017.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Prabhakara
Atreya at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: January 6, 2017.
Janice M. Soreth,
Associate Commissioner for Special Medical
Programs.
[FR Doc. 2017–00476 Filed 1–11–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01).
Date: February 7, 2017.
E:\FR\FM\12JAN1.SGM
12JAN1
3800
Federal Register / Vol. 82, No. 8 / Thursday, January 12, 2017 / Notices
Time: 1:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Julio Aliberti, Ph.D.,
Scientific Review Officer, Scientific Review
Program, DEA/NIAID/NIH/DHHS, 5601
Fishers Lane, MSC–9823, Rockville, MD
20852, 301–761–7322, alibertijc@
niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Peer Review Meeting.
Date: February 9, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Vasundhara Varthakavi,
DVM, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of
Extramural Activities, Room 3E70, National
Institutes of Health, NIAID, 5601 Fishers
Lane, MSC 9823, Bethesda, MD 20892–9823,
(240) 669–5020, varthakaviv@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 6, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–00477 Filed 1–11–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration (SAMHSA)
mstockstill on DSK3G9T082PROD with NOTICES
Advisory Committee for Women’s
Services (ACWS); Notice of Meeting
Pursuant to Public Law 92–463,
notice is hereby given of a meeting of
the Substance Abuse and Mental Health
Services Administration’s (SAMHSA)
Advisory Committee for Women’s
Services (ACWS) on February 1, 2017.
The meeting will include discussions
on the National Institutes of Health
(NIH) women and girls research
agendas; a Legislative update and an
overview of the Cures Act; an overview
of the Surgeon General’s Report; a
presentation on physical health/
behavioral health integration activities;
and a conversation with the Deputy
Assistant Secretary for Mental Health
and Substance Use.
The meeting is open to the public and
will be held at SAMHSA, 5600 Fishers
Lane, Rockville, MD 20857, in
Conference Room 5N76. Attendance by
VerDate Sep<11>2014
18:28 Jan 11, 2017
Jkt 241001
the public will be limited to space
available. Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions should be forwarded to the
contact person (below) by January 18,
2017. Oral presentations from the public
will be scheduled at the conclusion of
the meeting. Individuals interested in
making oral presentations are
encouraged to notify the contact person
on or before January 18, 2017. Five
minutes will be allotted for each
presentation.
The meeting may be accesed via
telephone. To attend on site, obtain the
call-in number and access code, submit
written or brief oral comments, or
request special accommodations for
persons with disabilities, please register
on-line at https://nac.samhsa.gov/
Registration/meetingsRegistration.aspx,
or communicate with SAMHSA’s
Designated Federal Officer, Ms. Nadine
Benton (see contact information below).
Substantive meeting information and
a roster of Committee members may be
obtained either by accessing the
SAMHSA Committees’ Web https://
www.samhsa.gov/about-us/advisorycouncils/meetings, or by contacting Ms.
Benton.
Committee Name: Substance Abuse
and Mental Health Services
Administration Advisory Committee for
Women’s Services (ACWS).
Date/Time/Type: Wednesday,
February 1, 2017, from: 9:00 a.m. to 4:45
p.m. EDT, OPEN.
Place: SAMHSA, 5600 Fishers Lane,
Conference Room 5N76, Rockville,
Maryland 20857.
Contact: Nadine Benton, Designated
Federal Official, SAMHSA’s Advisory
Committee for Women’s Services, 5600
Fishers Lane, Rockville, MD 20857,
Telephone: (240) 276–0127, Fax: (240)
276–2252, Email: nadine.benton@
samhsa.hhs.gov.
CDR. Carlos Castillo,
Committee Management Officer, Substance
Abuse and Mental Health, Services
Administration.
[FR Doc. 2017–00520 Filed 1–11–17; 8:45 am]
BILLING CODE 4162–20–P
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
DEPARTMENT OF THE INTERIOR
Fish and Wildlife Service
[FWS–R5–R–2016–N134; BAC–4333–99]
Plum Tree Island National Wildlife
Refuge, Poquoson, VA;
Comprehensive Conservation Plan and
Environmental Assessment
Fish and Wildlife Service,
Interior.
ACTION: Notice of availability; request
for comments.
AGENCY:
We, the U.S. Fish and
Wildlife Service (Service), announce the
availability of a draft comprehensive
conservation plan (CCP) and
environmental assessment (EA) for
Plum Tree Island National Wildlife
Refuge (NWR) for public review and
comment. Plum Tree Island NWR is
located in Poquoson, Virginia, and is
administered by staff at Eastern Virginia
Rivers NWR Complex based in Warsaw,
Virginia. The draft CCP and EA
describes two alternatives for managing
Plum Tree Island NWR for the next 15
years. Alternative B is identified as the
Service-preferred alternative. Also
available for public review and
comment are the draft compatibility
determinations, which are included as
appendix B in the draft CCP and EA.
DATES: To ensure consideration of your
written comments, please send them by
March 13, 2017. We will also hold
public meetings. We will announce
those meetings and other opportunities
for public input in local news media,
via our project mailing list, and on the
refuge planning Web site: https://
www.fws.gov/refuge/Plum_Tree_Island/
what_we_do/conservation.html.
ADDRESSES: You may submit comments
or requests for copies or more
information by any of the following
methods. You may request hard copies
or a CD–ROM of the documents.
Email: EasternVirginiaRiversNWRC@
fws.gov. Please include ‘‘Plum Tree
Island CCP’’ in the subject line of the
message.
U.S. Mail: Meghan Powell, Natural
Resource Planner, U.S. Fish and
Wildlife Service, P.O. Box 1030,
Warsaw, VA 22572.
Fax: Attention: Meghan Powell, 804–
333–3396.
In-Person Drop-off, Viewing, or
Pickup: Call Meghan Powell at 804–
313–7729, or Andy Hofmann, Refuge
Manager, at 804–333–1470, extension
112, during regular business hours to
make an appointment to view the
document.
FOR FURTHER INFORMATION CONTACT:
Meghan Powell, Natural Resource
SUMMARY:
E:\FR\FM\12JAN1.SGM
12JAN1
]]>Agencies
[Federal Register Volume 82, Number 8 (Thursday, January 12, 2017)]
[Notices]
[Pages 3799-3800]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-00477]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01).
Date: February 7, 2017.
[[Page 3800]]
Time: 1:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Julio Aliberti, Ph.D., Scientific Review
Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, 5601 Fishers
Lane, MSC-9823, Rockville, MD 20852, 301-761-7322,
alibertijc@niaid.nih.gov.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Peer Review Meeting.
Date: February 9, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Vasundhara Varthakavi, DVM, Ph.D., Scientific
Review Officer, Scientific Review Program, Division of Extramural
Activities, Room 3E70, National Institutes of Health, NIAID, 5601
Fishers Lane, MSC 9823, Bethesda, MD 20892-9823, (240) 669-5020,
varthakaviv@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: January 6, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-00477 Filed 1-11-17; 8:45 am]
BILLING CODE 4140-01-P
